699810 | PHAD™-504
Monophosphoryl Lipid A-504

Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
PHAD™-504
Monophosphoryl Lipid A-504
PHAD™-504 was designed as a synthetic structural analog of detoxified MPLA derived from E. coli lipopolysaccharide (LPS). It is structurally similar to PHAD™, differing only in the length of a single fatty acid chain. As expected, the activity of PHAD™-504 is quite similar to that of PHAD™, making the two products interchangeable as adjuvants in vaccine or immunotherapy formulations.
Ji Y, An J, Hwang D, Ha DH, Lim SM, Lee C, Zhao J, Song HK, Yang EG, Zhou P, Chung HS. Metabolic engineering of Escherichia coli to produce a monophosphoryl lipid A adjuvant. Metab Eng. 2020 Jan;57:193-202. doi: 10.1016/j.ymben.2019.11.009. Epub 2019 Nov 28. PMID: 31786244; PMCID: PMC6960009.
PubMed ID: 31786244- Certificate of Analysis (Lot No. 699810P-1MG-A-010 and 5087PGA010)
- Certificate of Analysis (Lot No. 699810P-5MG-A-010 and 5087PHA010)
- Certificate of Analysis (Lot No. 699810P-1MG-B-010 and 5087PGB010)
- Certificate of Analysis (Lot No. 699810P-5MG-B-010 and 5087PHB010)
- Certificate of Analysis (Lot No. 699810P-5MG-C-010 and 5087PHC010)
- Certificate of Analysis (Lot No. 699810P-1MG-C-010 and 5087PGC010)
- Certificate of Analysis (Lot No. 699810P-5MG-D-010 and 5087PHD010)
- Certificate of Analysis (Lot No. 699810P-1MG-E-010 and 5087PGE010)
- Certificate of Analysis (Lot No. 699810P-1MG-F-010 and 5087PGF010)